Euclises Pharmaceuticals, Inc. (Euclises) is a drug discovery and development company focused on novel cyclooxygenase-2 (COX-2) inhibitors for use in the oncology setting. Euclises has developed a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company is currently headquartered within the BioGenerator Accelerator Labs at CORTEX.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/09/14 | $1,300,000 | Series A |
ABC Laboratories Cultivation Capital St. Louis Arch Angels | undisclosed |
